These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 110736)

  • 1. Action of radiation or alkylating agents on LSA lymphoma during growth.
    Maruyama Y
    Int J Radiat Oncol Biol Phys; 1979 Feb; 5(2):215-20. PubMed ID: 110736
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence for reinitiation of proliferative activity following alkylation or radiation.
    Maruyama Y
    Int J Radiat Oncol Biol Phys; 1976; 1(9-10):903-9. PubMed ID: 977421
    [No Abstract]   [Full Text] [Related]  

  • 3. Study of in vivo tumor state and response to therapy by analysis of DNA distribution.
    Maruyama Y; Raju MR; Bains E; Jett J
    Cancer Treat Rep; 1976 May; 60(5):579-84. PubMed ID: 991146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antitumor effects of peptichemio and other alkylating agents.
    Schmid FA; Banks SE; Stock CC
    Cancer Treat Rep; 1977; 61(3):473-5. PubMed ID: 872145
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose alkylating agent therapy: a review of clinical experiences.
    Cornbleet MA; Leonard RC; Smyth JF
    Cancer Drug Deliv; 1984; 1(3):227-38. PubMed ID: 6399859
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal potentiation of the antitumor activity of alkylating drugs.
    Rutman RJ; Ritter CA; Avadhani NG; Hansel J
    Cancer Treat Rep; 1976 May; 60(5):617-8. PubMed ID: 991151
    [No Abstract]   [Full Text] [Related]  

  • 7. Recent advances in chemotherapy of lymphoma.
    Lenhard RE; Owens AH
    Johns Hopkins Med J; 1967 Aug; 121(2):136-40. PubMed ID: 5340335
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chemotherapy in the terminal stages of tumors].
    Astrakhan VI; Garin AM; Vvedenskaia NA; Bychkov MB
    Vopr Onkol; 1968; 14(6):92-6. PubMed ID: 4881119
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of WR-2721 in radiotherapy and/or chemotherapy.
    Yuhas JM; Spellman JM; Culo F
    Cancer Clin Trials; 1980; 3(3):211-6. PubMed ID: 6254681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent therapy for Hodgkin's disease.
    Carter SK; Livingston RB
    Arch Intern Med; 1973 Mar; 131(3):377-87. PubMed ID: 4631683
    [No Abstract]   [Full Text] [Related]  

  • 11. Endotoxin stimulation in patients with lymphoma: correlation with the myelosuppressive effects of alkylating agents.
    DeConti RC; Kaplan SR; Calabresi P
    Blood; 1972 May; 39(5):602-9. PubMed ID: 5067305
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
    Goldenberg GJ
    Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of age of host on the chemotherapy of murine myeloma LCP-1.
    Teller MN; Bowie M; Mountain IM
    J Gerontol; 1974 Jul; 29(4):360-5. PubMed ID: 4833754
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour.
    Stanley JA; Shipley WU; Steel GG
    Br J Cancer; 1977 Jul; 36(1):105-13. PubMed ID: 889677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug therapy of malignant lymphoma].
    Ogawa M; Inagaki J
    Rinsho Hoshasen; 1985 Oct; 30(11):1317-32. PubMed ID: 2418229
    [No Abstract]   [Full Text] [Related]  

  • 17. [Association of intralymphatic radiotherapy and alkylating agents in the treatment of retroperitoneal hematosarcomas].
    Bonadonna G; Chiappa S; Di Pietro S; Marano O; Molinari R; Uslenghi C
    Nouv Rev Fr Hematol; 1967; 7(3):381-92. PubMed ID: 4229322
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of acute 60Co, low dose rate CF-252 and CS-137 radiation on LSA ascites lymphoma in vivo.
    Maruyama Y; Feola JM; Magura C; Onomura CI; Beach JL
    Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1991-7. PubMed ID: 4055456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trials of WR-2721 with alkylating agent chemotherapy.
    Glick JH; Glover DJ; Weiler C; Blumberg A; Nelson D; Yuhas JM; Kligerman M
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):575-80. PubMed ID: 6286556
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.